Law360, New York (January 09, 2007, 12:00 AM ET) -- In an 8-1 decision that may lead more licensees to challenge patents, the Supreme Court on Tuesday sided with biotech company MedImmune Inc. in a royalty dispute with Genentech Inc. over an infant respiratory drug.
The ruling came amid wrangling between business and government over whether patents are too easily approved, preventing rather than inspiring inventions.
The biotech rivals have been battling over a Genentech patent covering Synagis, one of MedImmune’s blockbuster drugs, which brings in more than $1 billion in sales each year.
The High...
Supreme Court Ruling Bolsters Licensee Rights
To view the full article, take a free trial now.
